Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro Corp ...

StockNews.com upgraded shares of Globus Medical (NYSE:GMED – Free Report) from a hold rating to a buy rating in a research ...

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...

and regenerative biologic products comprising of allografts and synthetic alternatives. Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement ...

Wall Street analysts expect Globus Medical (GMED) to post quarterly earnings of $0.76 per share in its upcoming report, which indicates a year-over-year increase of 26.7%. Revenues are expected to be ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Globus Medical (GMED) reports results for the quarter ended December 2024. While this widely-known consensus ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.